GL-3 Molecule (Prescription Only) — 10mg to 60mg Options

Triple-Incretin Therapy for Advanced Weight Management & Metabolic Support

Formulation & Available Options

GL-3 is supplied in standardized 10mg vials, with each vial reconstituted to a total volume of 1mL.

Concentration of Every Vial: 10mg / 1mL
Dosing Conversion: 10 units = 1mg GL-3

Choose the total amount that best matches your prescribed treatment plan:

• GL-3 10mg: 1 × 10mg vial

• GL-3 20mg: 2 × 10mg vials

• GL-3 30mg: 3 × 10mg vials

• GL-3 40mg: 4 × 10mg vials

• GL-3 50mg: 5 × 10mg vials

• GL-3 60mg: 6 × 10mg vials

Because every vial contains 10mg and is reconstituted to the same 1mL volume, the concentration and unit conversion remain identical regardless of which total quantity is selected.

Classification: Prescription Only — Requires Provider Consultation & Approval

What Is GL-3 Therapy?

GL-3 is a prescription triple-receptor incretin therapy that targets three important metabolic signaling pathways:

• GLP-1 receptor

• GIP receptor

• Glucagon receptor

This combination of receptor activity is being studied for its effects on body weight, appetite regulation, glycemic control, and energy metabolism.

GL-3 may be incorporated into a provider-directed weight-management program when clinically appropriate. Treatment is individualized based on response, tolerability, metabolic health, and patient goals.

All GL-3 products require clinical consultation and prescription approval prior to dispensing.

🔬 Key Research-Based Mechanisms

🔥 Triple-Receptor Activation & Weight Reduction

GLP-1 and GIP receptor activity contributes to appetite regulation and satiety, while glucagon receptor activity may contribute additional effects on energy metabolism.

Jastreboff et al., 2023, New England Journal of Medicine — In a phase 2 trial of retatrutide in adults with obesity, mean body-weight reductions reached 24.2% at 48 weeks in the 12mg treatment group.

🩸 Glycemic Control & Metabolic Health

Triple-receptor agonism has demonstrated substantial effects on glucose regulation and other cardiometabolic measures during clinical development.

Rosenstock et al., 2023, The Lancet — A phase 2 trial of retatrutide in adults with type 2 diabetes demonstrated substantial reductions in HbA1c and body weight across treatment groups.

🧠 Appetite & Energy-Intake Regulation

GLP-1 and GIP signaling interact with metabolic pathways involved in satiety, food intake, and nutrient handling. These effects contribute to the weight-loss response associated with incretin-based therapies.

Coskun et al., 2022, Cell Metabolism — Preclinical and early translational research describing the GIP/GLP-1/glucagon receptor agonist LY3437943 demonstrated integrated metabolic effects supporting its subsequent clinical development.

🧬 Energy Expenditure & Glucagon Signaling

The glucagon component distinguishes triple-receptor agonism from GLP-1–only and dual-incretin approaches. Glucagon receptor activation influences hepatic metabolism, lipid utilization, and energy expenditure, although its contribution to clinical weight loss continues to be investigated.

Hope et al., 2025, Nature Medicine — Human mechanistic investigation of retatrutide evaluated changes in energy intake and expenditure associated with treatment and weight reduction.

⚕️ Clinical Access & Prescription Protocol

GL-3 therapy requires provider oversight and prescription approval.

• Telehealth or clinical consultation required prior to dispensing

• Baseline laboratory testing may be recommended based on medical history

• Individualized dosing and titration

• Provider-directed assessment of response and tolerability

• Ongoing clinical monitoring and follow-up

Your prescribed dose may differ from another patient's dose. Always follow the dosing instructions provided by your prescribing clinician.

💉 Standardized Concentration & Dosing

Regardless of which quantity is purchased, every GL-3 vial is prepared identically.

Each Vial Contains: 10mg GL-3
Final Volume: 1mL
Final Concentration: 10mg/mL

Easy Unit Conversion

10 units = 1mg
20 units = 2mg
30 units = 3mg
40 units = 4mg
50 units = 5mg

This conversion remains the same for every vial in every package size.

Starting Protocol

A commonly prescribed starting dose in our clinical protocol is:

20 units once weekly = 2mg weekly

Dosing is individualized by the prescribing provider according to treatment response and tolerability.

Provider-Directed Titration

When appropriate, the prescribing provider may recommend maintaining the current dose while weight loss remains consistent. Dose adjustments may be considered when progress plateaus or when tolerability requires a lower dose.

Route: Subcutaneous injection
Preferred Site: Abdomen
Typical Program: 3–6 months with periodic reassessment

Do not increase or decrease your prescribed dose without following your provider-directed treatment plan.

Choose the Appropriate Program Size

The different GL-3 options contain the same medication at the same concentration. The only difference is the number of 10mg vials included.

Every vial: 10mg / 1mL

This standardized format makes it possible to purchase a quantity appropriate for the prescribed program without changing the concentration or dosing conversion between vials.

Compatible Protocol Additions

Depending on individual goals and clinical appropriateness, GL-3 may be incorporated into broader protocols that include:

KPV — Investigated for anti-inflammatory and gastrointestinal signaling.
Bettenworth et al., 2011, International Journal of Colorectal Disease — Experimental research has evaluated KPV and related melanocortin signaling for anti-inflammatory activity.

Tesamorelin — A GHRH analog with clinical evidence for reducing visceral adipose tissue in its studied populations.
Falutz et al., 2010, Journal of Clinical Endocrinology & Metabolism — Clinical trials demonstrated significant reductions in visceral adipose tissue with tesamorelin therapy.

MOTS-C — A mitochondrial-derived peptide being investigated for metabolic signaling, glucose utilization, and exercise-related physiology.
Lee et al., 2015, Cell Metabolism — Foundational research demonstrated effects of MOTS-C on cellular metabolism, insulin sensitivity, and metabolic homeostasis.

GHK-Cu — A copper-binding peptide studied primarily for tissue remodeling, wound healing, and regenerative signaling.
Pickart & Margolina, 2018, International Journal of Molecular Sciences — Reviewed evidence surrounding GHK-Cu and its potential roles in tissue remodeling and regenerative biology.

📦 What’s Included With Every Order

Your order includes the appropriate number of standardized 10mg GL-3 vials based on the quantity selected.

• 10mg option: 1 vial

• 20mg option: 2 vials

• 30mg option: 3 vials

• 40mg option: 4 vials

• 50mg option: 5 vials

• 60mg option: 6 vials

Also included:

• Appropriate bacteriostatic water for reconstitution

• Insulin syringes and alcohol swabs

• Sharps container bag

• Dosing, reconstitution, storage, and injection guidance

• Ongoing access to the prescribing clinical team

📧 Need Assistance?

Admin@Propeptides.com
480-400-6225

🛡️ One Standardized Concentration. Multiple Program Sizes. Provider-Directed Care.

Every GL-3 option uses the same standardized 10mg vial and the same 10mg/mL concentration.

The only difference is how many vials you receive.

Whether your prescribed program requires 10mg, 20mg, 30mg, 40mg, 50mg, or 60mg total, the preparation and unit conversion remain consistent from vial to vial.

10mg per vial. 1mL per vial. 10 units = 1mg.

Select the quantity appropriate for your prescribed program and follow your individualized treatment plan under clinical supervision.